[…]
Moderna (NASDAQ:MRNA) says the FDA has given the green light to begin the Phase 2 study on its redacted redacted vaccine (mRNA-1273).
It’s expected to start imminently, with the goal of a Phase 3 study to begin in early summer, and approval as soon as 2021.
This is important because Moderna is ahead of everyone else in the redacted vaccine battle.
https://seekingalpha.com/pr/17862704-moderna-reports-first-quarter-2020-financial-results-and-provides-business-updates